Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA6C8N
|
|||
| Drug Name |
LXE408
|
|||
| Synonyms |
SCHEMBL16822697; HY-131350; CS-0133456; FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C)=N1; 1799330-15-6; N-(4-Fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Visceral leishmaniasis [ICD-11: 1F54.0; ICD-10: B55.0; ICD-9: 85] | Phase 2 | [1] | |
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H18FN7O2
|
|||
| Canonical SMILES |
CC1=C(N=CC=C1)C2=CN3C(=NC(=N3)C4=C(C=CC(=C4)NC(=O)C5=C(N=C(O5)C)C)F)N=C2
|
|||
| InChI |
1S/C23H18FN7O2/c1-12-5-4-8-25-19(12)15-10-26-23-29-21(30-31(23)11-15)17-9-16(6-7-18(17)24)28-22(32)20-13(2)27-14(3)33-20/h4-11H,1-3H3,(H,28,32)
|
|||
| InChIKey |
GNVVPYCWVLCWKV-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leishmania major Proteasome (Leishm Proteasome) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Novartis. | |||
| REF 2 | Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Oct 8;63(19):10773-10781. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.